Enhanced Assay for Lyme Disease IgM / IgG Antibodies
Monday, February 22, 2021
Laboratory Alliance of Central New York is pleased to announce that, effective 02/22/2021, Lyme IgM/IgG antibodies are measured using an enhanced assay. In addition to capturing antibodies against variable major protein-like sequence (VIsE), the enhanced assay now captures antibodies against outer surface protein (OspC).
VIsE antigens produce a strong antibody response at all stages of Lyme disease, including during the early stage, and they are expressed in B. burgodorferi and B. garinii. The OspC is an immunodominant antigen of the IgM response during early-stage infection. The OspC antigen is a recombinant protein from B. afzelii and shares a high degree of homology with the B. burgdorferi.
The order codes and specimen requirements have not changed.
For questions about the Lyme Disease IgM/IgG Antibodies assay, please contact Bodhraj Acharya, Ph.D., MT(ASCP), Manager, Chemistry and Referral Testing, at 315- 410-7028 or BodhrajAcharya@lacny.com.